Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

19.25USD
19 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$19.25
Open
$18.88
Day's High
$19.69
Day's Low
$18.82
Volume
58,676
Avg. Vol
63,142
52-wk High
$22.85
52-wk Low
$2.78

Select another date:

Wed, Sep 5 2018

ProQR soars as childhood blindness drug succeeds in early trial

Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.

UPDATE 1-ProQR soars as childhood blindness drug succeeds in early trial

Sept 5 Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.

ProQR drug for rare childhood blindness succeeds in early trial

Sept 5 Dutch drug developer ProQR Therapeutics NV said on Tuesday its interim analysis showed that an early-stage trial of an experimental treatment for a rare form of childhood blindness was successful in improving vision.

BRIEF-ProQR Announces Q1 Loss Per Share Eur 0.34

* AT MARCH 31, 2018, PROQR HELD CASH AND CASH EQUIVALENTS OF €38.0 MILLION, COMPARED TO €48.1 MILLION AT DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

BRIEF-ProQR Provides Enrollment Update On QR-110 Clinical Trial

* PROQR PROVIDES ENROLLMENT UPDATE ON QR-110 CLINICAL TRIAL AND HIGHLIGHTS OPHTHALMOLOGY PRESENTATIONS AT ARVO

Select another date: